Literature DB >> 27926725

An update on obtaining and enforcing therapeutic antibody patent claims.

Theresa Gresl1, Ulrich Storz2, Colin Sandercock3.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27926725     DOI： 10.1038/nbt.3735

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope.

Authors:  Colin G Sandercock; Ulrich Storz
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908
  1 in total
  3 in total

Review 1.  The impact of structural biology in medicine illustrated with four case studies.

Authors:  Tiancen Hu; Elizabeth R Sprague; Michelle Fodor; Travis Stams; Kirk L Clark; Sandra W Cowan-Jacob
Journal:  J Mol Med (Berl)       Date:  2017-07-01       Impact factor: 4.599

2.  Allergan's Mohawk evergreening patent deal draws criticism, but ultimately may flop.

Authors:  Eva von Schaper
Journal:  Nat Biotechnol       Date:  2017-11-09       Impact factor: 54.908

3.  An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?

Authors:  Evelien Moorkens; Arnold G Vulto; Isabelle Huys
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.